🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

OS is a poor outcome measure for this population given the median advanced age and competing risks of mortality. Also, the study only enrolled high risk patients based on pathology.

Congratulations to the #C-POST team!!! Huge step forward for patients with high risk, resected #cscc #skin #cancer Regeneron Trans Tasman Radiation Oncology Group The ASCO Post NEJM

“Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib should be considered a new standard of care for Stage IV BRAF V600E-mutated anaplastic thyroid cancer,” says our Mark Zafereo, MD at #ASCO25. Read more about this practice-changing research:

Researchers at MD Anderson are always innovating new approaches to treatments for head and neck cancers. Drs. Neil Gross and Katherine Hutcheson will share the latest on Sunday, June 1 at 1 p.m. in booth 10059. #ASCO25 #EndCancer (4/6) Neil D. Gross, MD, FACS

Work 💪🏻to be done to prove the potential value of #neoadjuvant #C-PRE NRG Oncology #HN014 Time to enroll! NCI Cancer Control CCTG Trans Tasman Radiation Oncology Group

At #ASCO25, Katherine Hutcheson, Ph.D., presented results from the Phase IV PRO-ACTIVE trial, which compared timing and intensity of swallow therapy for patients with head and neck cancer receiving radiation. No meaningful difference was found between reactive and proactive

Correct. 💯 postop

Prof. Roda Amaria places neoadjuvant data from 3 studies in resectable melanoma in context: importance of harmonizing pathological assessments, especially with intratumoral therapy, and Neoadjuvant Setting is CRITICAL to guide IO Drug and Biomarker Development

Fantastic to see findings from the C-POST trial that could prove game-changing for the many people at high risk of recurrence of cutaneous squamous cell carcinoma published in NEJM. Congrats to Prof Danny Rischin Peter Mac Cancer Centre & the research team. hubs.ly/Q03rBgRR0

Boom!💥 ⁦FDA⁩ approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma, ushering in a new standard of care for the first time in decades. fda.gov/drugs/resource…

The standard of care has finally changed for patients with resectable head and neck #cancer!! Congratulations Ravi Uppaluri, MDPhD and all the #KN-689 investigators. fda.gov/drugs/resource…

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery + risk adapted adjuvant therapy. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS.ascopubs.org/doi/10.1200/JC…

EFS has led to approvals in other solid tumors, most notably NSCLC.

OS is not a good endpoint for CSCC given the advanced average patient age and competing risks of death. CSCC is also uniquely responsive to IO and C-POST allowed crossover.

Here it is! KEYNOTE-689 primary publication online now NEJM. It’s been an incredible journey with DAdkins Siteman Cancer Center @WUSM. All started in early 2010s / now with U.S. FDA approval and a new standard of care! Dana-Farber News Brigham and Women's Hospital Brigham and Women’s Department of Surgery

nejm.org/doi/full/10.10…

SOC changed!

Fantastic meeting!!! #neoadjuvant

The American Head and Neck Society (AHNS) strongly supports the continued and widespread use of the human papillomavirus (HPV) vaccine as a vital public health measure to prevent HPV-associated cancers. Read the full statement here: buff.ly/92YmSEc #AHNS #HPVvaccines

The U.S. FDA has approved perioperative pembrolizumab adjuvant radiotherapy for adult patients with HNSCC with 🔹resectable, locally advanced disease 🔹who express PD-L1 with a CPS of at least 1, per an FDA-approved test. 🔗 onclive.com/view/fda-appro… #hnscc #oncology